compil event come
soon biotech coverag
follow highlight
note highlight event catalyst biotechnolog coverag anticip
soon well highlight week
american associ studi liver diseas san francisco nov liver-
bayko mo pt risk-adjust dcf-deriv spring bank biopharma sbph bayko mo
expect thr- debat like topic interest mdgl plenari present
vktx late breaker also look forward plenti fxr data includ first look novarti
phase nash studi think hbv could garner attent janssen/arwr deal
conjunct meet jmp host bu tour nov contact jmp sale
repres detail
data intern respiratori syncyti viru symposium ashevil nov
gave sneak peek data announc kick phase challeng studi
data color phase sae headach common ae discontinu due
dose twice daili regardless food phase dose higher
see note
prior expect late septemb expect phase result subject treat ba
monotherapi studi confid posit result placebo-adjust ldl-c
lower continu good safety/toler
assign probabl success ba program
idra aprilaki mo pt expand data trial
releas later quarter
discuss see addit analys present esmo previous releas cohort data
howev addit data report patient
butler mo pt risk-adjust dcf-deriv result
two ganaxolon phase trial iv oral track read last patient
last visit magnolia iv late octob assum typic week data analysi period
expect result late novemb decemb complet enrol note amarylli trial result
oral ganaxolon mild-to-moder expect announc magnolia result
continu view readout transform stock remain enthusiast
probabl success iv oral formul
report read conjunct import disclosur inform includ attest regul analyst certif
magnolia expect magnitud benefit compar seen phase trial
sage brexanolon point placebo adjust improv ham-d score hour
base manag prior comment expect total approxim patient
enrol magnolia optim dose level given small sampl size expect
result achiev statist signific
ovid ovid butler mo pt risk-adjust dcf-deriv result quarter
phase trial evalu encephalopath epilepsi
small expect adult patient trial enrol divers set epilept
bayko mo pt risk-adjust dcf-deriv follow-up data come
oral present oct asn kidney week annual meet detail long-term effect
sparsentan fsg patient see note
long-term data phase duet studi show sparsentan continu lower proteinuria
egfr continu look stabl fsg patient
week recap
monitor unit trial indic equival bioavail during/near seizur liberv
buccal diazepam note
detail present american epilepsi societi meet nov dec
late-break continu view liberv compel product provid
demonstr clinic advantag standard care continu assum fda approv
maintain revenu project peak sale
highlight cash see note
still track updat full phase data efgartigimod itp
phase aml
axov scienc axon butler mo pt risk-adjust dcf-deriv first patient dose
axo-lenti-pd trial initi result expect see note
impress phase data bcrx oral kallikrein inhibitor term use rescu med
safeti onset action may slower inject option think
patient want tri acut treatment option see note
host call dr marc riedl clinic director haea angioedema center uc
san diego reiter high enthusiasm patient oral option contact jmp
secur sale repres copi full transcript
biolinerx ltd blrx aprilaki mo pt dcf sotp-deriv present promis result
esmo plu keytruda metastat pancreat adenocarcinoma mpdac
partial respons diseas control rate dcr observ median
overal surviv mo month six-month surviv rate second line patient
highest mo month compar favor histor month current
approv chemotherapi addit biopsi data provid support elev immun
respons propos moa see note
data extens studi acr continu support lenabasum system sclerosi ssc
dermatomyos dm see note
open-label extens data phase studi ssc dm patient show continu
improv key efficaci endpoint notabl mrss primari endpoint on-going phase
studi ssc cdasi physician/pati global assess dm
open-label natur lack control potenti influenc background med make
interpret result difficult separ second plenari nacfc address
issu inflamm cf patient highlight lenabasum one excit
agent see note
dbvt bayko mo pt risk-adjust dcf-deriv right time dbvt
submit bla viaskin peanut anticip accept review year end absenc
pdufa see note
think accept bla could meaning de-risk event support
upward momentum stock allergen extract viaskin peanut exempt pdufa
therefor fda commit typic pdufa time line although manag
idera pharmaceut idra aprilaki mo pt data trial
present esmo
although new addit patient character deeper analys subject alreadi
present indic within tilsotolimod trial patient experienc respons tumor
distant locat inject indic evid abscop effect effect
observ patient respond includ two complet respons individu
case respons highlight imag show dramat reduct tumor volum
see note
bayko mp risk-adjust dcf-deriv updat phase data pemigatinib
inhibitor esmo cholangiocarcinoma bladder
cancer see note
show best orr median os month
respect seem like win vis-a-vi expect orr first-lin standard
care second-lin chemotherapi show best orr two
week on/on week schedul expect could improv continu dose
seen fgfr inhibitor indic
give first glimps parkinson candid note
addit demonstr favor safety/toler profil parkinson diseas patient
multiple-ascend dose trial also show indic improv motor symptom
complic dyskinesia symptom return follow cessat treatment
result earli view posit step look forward futur
data phase ii run-hn trial tipifarnib hras-mut hrasm head neck squamou
cell carcinoma hnscc well initi data patient scc esmo see note
respons rate hnscc degrad significantli previou data releas vs
evalu patient vs basi possibl due issu toler
compani plan reduc dose mg bid go forward trial plan
pivot aim-hn trial major respons seen patient dose one patient
pr start dose three other achiev pr reduc mg bid give
us confid protocol chang help maxim therapeut window tipifarnib
prevent respons rate degrad
first data six patient scc hnscc also present two vulva scc two
penil scc one skin scc one cutan scc patient consid evalu
respons one penil scc achiev pr cutan scc experienc
loxo oncolog loxo aprilaki mo pt risk-adjust dcf sotp-deriv present
updat phase i/ii data select trk inhibitor larotrectinib patient trk fusion-posit solid
tumor esmo see note
orr observ primari cohort maintain inclus
supplementari cohort mdor yet reach median follow
month mpf month primari dataset
overal data appear show larotrectinib efficaci compet trk
inhibitor entrectinib rhhbi nc demonstr orr mpf month
leverag xr-odt technolog condit al cerebr palsi etc see note
neo announc in-licens n-desethyloxybutynin activ metabolit oxybutynin
act select muscarin receptor antagonist neo develop treat
ovid ovid butler mo pt risk-adjust dcf-deriv detail
star phase present aacap see note
believ new granular efficaci improv sleep motor function reinforc
signal benefit warrant advanc develop indic compani expect
particip end-of-phas discuss fda year end provid clariti
path phase develop also continu anticip result quarter
phase trial evalu encephalopath epilepsi
net revenu line consensu see note
reiter exondi revenu guidanc impli q-o-q
growth second phase launch low-hang fruit appear
pick new wave patient littl challeng dmd pipelin continu
posit momentum expect complet roll nda submiss golodirsen
begin pivot trial micro-dystrophin gene therapi also
sonic studi recorlev cush present european neuroendocrin associ
meet see note
respons rate continu rang term ufc normal depend
data cut detail cardiometabol readout present first time includ
statist signific improv dyslipidemia weight etc qtc prolong appear
consist ketoconazol manag expect look addit data
sonic march endo meet data double-blind placebo-control phase
logic trial
coverag compani built around cell-fre protein synthesi technolog see initi
report
xpresscf platform combin cell-fre protein synthesi abil incorpor non-
natur amino acid gener site-specif adc therapeut protein method
requir gener stabl cell line test new/modifi antibodi greatli reduc
time requir character clinic candid time discoveri ind
lead asset adc warhead link specif site use proprietari conjug
method inhibitor phase clinic studi r/r nhl mm stro-
anti-folr compani plan studi ovarian endometri cancer ind
expect later year
phase patient ds movement disord see note
discontinu ds indic fail phase trial see
increas risk lc-faod schedul pre-nda meet
financi result see note
growth new cf combo symdeko underli revenu growth cf franchis
roughli line consensu competit front nc deepen
commit cf take control stabl cftr modul partner glpg
yearexpect result subject treat bempedo acid monotherapi studi data date oliceridin acut updat data phase navig trial kit pdgfr-driven gist date larotrectinib nda ntrk-fusion cancer full data efgartigimod itp argxphas full data aml phase ctcl pdufa studi add-on therapi three-month data pnh patient receiv open-label phase second group first studi submiss tenapanor data phase tripl combo hair regrowth phase ii combin data nda top-line result data phase iia studi alopecia interim analysi pacritinib phase ii myelofibrosi opinion pacritinib phase ii trial eryaspas result result cbd oral solut childhood absenc result magnolia phase trial ganaxolon sever result amarylli trial ganaxolon moder result five day treatment ganaxolon refractori statu epilepticu result epilept encephalopathi includ dravet syndrom lennox-gastaut data phase trial entinostat/aromasin bc top-line data tnbc encor mad trial data cancer pt phase ii develop strategi data phase ii studi aml first-lin combin data phase ii studi r/r aml md combin data phase dose escal advanc solid tumor patient result nuplazid trial palisad rams data trial children age ii ahu proof-of-concept data phase i/ii cohort data lumasiran ole initi phase ii trial initi phase ii trial interim result efgartigimod interim result subcutan efgartigimod chronic autoimmun time nda submiss rest-on phase result phase iia combat studi combo keytruda pancreat initi lead-in period genesi phase scm autolog transplant result phase ib/ii studi combo tecentriq nsclcaprilaki biotechnolog
yearexpect updat data on-going phase trial avapritinib gist updat data phase trial avapritinib advanc sm preclin data fibrodysplasia ossifican progressiva least addit discoveri new pipelin combin data rcc phase ii combin data phase ii cantata studi combin cabozantinib pacritinib interim result registr path enrol second pivot studi line data phase dose escal solid hematolog data phase expans solid tumor driven kit phase ib rebastinib combo trial i/o chemotherapi phase ii trial eryaspas pancreat triplex data sot phase ii data allogen nda full data jakafi acut phase result lumateperon monotherapi bipolar depress studi phase result luateperon dementia-associ result multiple-rising-dos phase trial adjunct mild-to-moder phase iib top-lin data sadal r/r aa selinexor r/r mm base storm phase dose-escal updat on-going phase ii trial tipifarnib hra mutant clinic data tipifarnib hematolog registr trial tipifarnib hra mutant hnscc poc studi tipifarnib hra mutant squamou non-smal cell lung cancer phase i/ii clinic data patient acquir resist phase clinic trial patient acquir resist submit european complet phase head-to-head studi tremfya vs cosentyx glaucoma phase data movement interim data cohort data phase mg inarigivir co-administ data next develop result hetlioz smith-mageni result tradipit approv decis teza/iva studi ole cohort mg phase achiev trial end pivot phase ii trial avapritinib indol smolder sm end merger end merger ind data phase trial debbayko biotechnolog
